Your browser is no longer supported. Please, upgrade your browser.
VVUS VIVUS, Inc. daily Stock Chart
Index- P/E- EPS (ttm)-0.38 Insider Own2.20% Shs Outstand107.26M Perf Week-3.90%
Market Cap79.47M Forward P/E- EPS next Y-0.57 Insider Trans421.95% Shs Float103.16M Perf Month-7.84%
Income-39.80M PEG- EPS next Q-0.11 Inst Own22.50% Short Float4.77% Perf Quarter92.39%
Sales50.30M P/S1.58 EPS this Y-228.60% Inst Trans-0.34% Short Ratio3.48 Perf Half Y55.98%
Book/sh-0.18 P/B- EPS next Y-26.70% ROA-15.10% Target Price1.50 Perf Year-39.27%
Cash/sh1.95 P/C0.38 EPS next 5Y0.80% ROE695.90% 52W Range0.33 - 1.26 Perf YTD47.41%
Dividend- P/FCF- EPS past 5Y27.50% ROI1.40% 52W High-41.43% Beta0.65
Dividend %- Quick Ratio7.90 Sales past 5Y100.60% Gross Margin72.70% 52W Low122.49% ATR0.04
Employees52 Current Ratio8.70 Sales Q/Q-55.90% Oper. Margin-13.50% RSI (14)45.82 Volatility4.15% 5.41%
OptionableYes Debt/Eq- EPS Q/Q-903.90% Profit Margin-79.80% Rel Volume0.20 Prev Close0.73
ShortableYes LT Debt/Eq- EarningsAug 07 AMC Payout- Avg Volume1.42M Price0.74
Recom3.00 SMA20-0.42% SMA50-0.55% SMA20024.80% Volume284,546 Change1.49%
May-04-16Downgrade WallachBeth Buy → Hold
Nov-05-15Upgrade WallachBeth Hold → Buy $2.30 → $2.80
Jul-31-15Reiterated RBC Capital Mkts Outperform $6 → $4
Jan-23-15Initiated RBC Capital Mkts Outperform $6
Feb-25-14Reiterated WallachBeth Hold $11 → $8
Nov-15-13Initiated WallachBeth Hold $11
Oct-03-13Upgrade Cowen Hold → Outperform $19
Jul-19-13Downgrade Needham Buy → Hold
Jan-18-13Reiterated MLV & Co Buy $40 → $21
Sep-24-12Reiterated Needham Buy $38 → $32
Jul-19-12Reiterated MLV & Co Buy $34 → $40
Jul-18-12Reiterated Rodman & Renshaw Mkt Outperform $39 → $52
Jul-18-12Downgrade Brean Murray Buy → Hold
Apr-30-12Reiterated MLV & Co Buy $30 → $34
Feb-23-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $39
Feb-23-12Upgrade Brean Murray Sell → Hold $2
Feb-23-12Reiterated MLV & Co Buy $22 → $30
Feb-23-12Reiterated JMP Securities Mkt Outperform $16 → $45
Jan-17-12Reiterated MLV & Co Buy $16 → $22
Jan-05-12Initiated Rodman & Renshaw Mkt Perform
Jul-11-18 09:14AM  VIVUS' PAH Candidate Data Positive in Early Stage Study Zacks -5.14%
08:31AM  VIVUS, Inc. (VVUS) Soars: Stock Adds 10.1% in Session Zacks
Jul-10-18 07:30AM  VIVUS Announces Positive Results from a Phase 1 Clinical Trial of VI-0106 GlobeNewswire +10.14%
Jun-15-18 07:30AM  3 Biotech Stocks Up in the Past Month on Industry Turnaround InvestorPlace
Jun-11-18 09:32AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:51AM  Can The Uptrend Continue for VIVUS (VVUS)? Zacks
07:30AM  VIVUS Executes on its Strategic Vision with the Closing of its Acquisition of PANCREAZE® and Previously Announced Financing Transaction GlobeNewswire
Jun-05-18 10:10AM  3 Biotech Stocks Up in the Past Month on Industry Turnaround Zacks
May-30-18 07:25AM  Complimentary Technical Snapshots on VIVUS and Three More Biotech Stocks ACCESSWIRE
May-25-18 08:44AM  VIVUS (VVUS) in Focus: Stock Moves 5.6% Higher Zacks
May-22-18 07:53AM  Biotech CEO Presents: Mercks $500M Pain, Our Potential Gain ACCESSWIRE +6.81%
May-17-18 08:00AM  Todays Research Reports on Stocks to Watch: Eleven Biotherapeutics and VIVUS ACCESSWIRE -5.41%
May-13-18 09:41PM  Edited Transcript of VVUS earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-10-18 10:29AM  VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters Zacks
May-08-18 07:09PM  Vivus: 1Q Earnings Snapshot Associated Press -7.11%
04:05PM  VIVUS Reports First Quarter 2018 Financial Results GlobeNewswire
May-04-18 04:05PM  VIVUS Announces Date of 2018 Annual Meeting GlobeNewswire
May-03-18 08:05AM  VIVUS, Inc., New Team, New Acquisition Agreement, New Product, Analysts Review ACCESSWIRE +10.87%
07:30AM  Blog Exposure - VIVUS to Acquire Janssen Pharmas PANCREAZE(R) Capsules in the United States and Canada ACCESSWIRE
May-02-18 08:10AM  Todays Research Reports on Stocks to Watch: Avinger and VIVUS ACCESSWIRE -14.74%
May-01-18 07:05AM  VIVUS Expands its Commercial Product Portfolio with the Acquisition of PANCREAZE® GlobeNewswire +46.68%
07:00AM  VIVUS Restructures Debt and Gains Access to New Capital GlobeNewswire
Apr-30-18 04:20PM  VIVUS Strengthens Executive Leadership Team Marketwired
Apr-25-18 04:05PM  VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, May 8, 2018 Marketwired
Apr-12-18 09:50AM  Why Is VIVUS (VVUS) Down 18% Since its Last Earnings Report? Zacks
Mar-13-18 04:15PM  Vivus reports 4Q loss Associated Press -9.46%
04:05PM  VIVUS Reports Fourth Quarter 2017 Financial Results Marketwired
Feb-09-18 08:30AM  Todays Research Reports on Trending Tickers: Arena Pharmaceuticals and VIVUS ACCESSWIRE -10.73%
Dec-26-17 04:05PM  VIVUS Announces Change in Leadership Marketwired
Dec-22-17 11:51AM  ETFs with exposure to VIVUS, Inc. : December 22, 2017 Capital Cube
Dec-11-17 02:15PM  ETFs with exposure to VIVUS, Inc. : December 11, 2017 Capital Cube
Dec-01-17 10:49AM  ETFs with exposure to VIVUS, Inc. : December 1, 2017 Capital Cube
Nov-20-17 01:34PM  ETFs with exposure to VIVUS, Inc. : November 20, 2017 Capital Cube
Nov-13-17 06:55PM  Edited Transcript of VVUS earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-10-17 12:55PM  ETFs with exposure to VIVUS, Inc. : November 10, 2017 Capital Cube
Nov-09-17 09:09AM  VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down Zacks
08:45AM  VIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 Capital Cube
Nov-07-17 04:57PM  Vivus reports 3Q loss Associated Press
04:05PM  VIVUS Reports Third Quarter 2017 Financial Results Marketwired
10:40AM  VIVUS, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-17 07:00AM  VIVUS Completes Tacrolimus Pre-IND Meeting With FDA Marketwired
Oct-31-17 08:00AM  VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 7, 2017 Marketwired +5.59%
Oct-30-17 12:22PM  ETFs with exposure to VIVUS, Inc. : October 30, 2017 Capital Cube -6.75%
Oct-20-17 10:28AM  ETFs with exposure to VIVUS, Inc. : October 20, 2017 Capital Cube
Oct-09-17 12:11PM  ETFs with exposure to VIVUS, Inc. : October 9, 2017 Capital Cube
Oct-06-17 09:17AM  VIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Capital Cube
Sep-28-17 09:25AM  Orexigen's (OREX) Contrave Sales Improving on Promotions Zacks
Sep-08-17 08:00AM  VIVUS, Aggressive Marketing For Approved Drugs, Milestone for Tacrolimus, Pipeline Analysis ACCESSWIRE
Sep-06-17 06:09PM  VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug Zacks
04:05PM  VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension Marketwired
Sep-05-17 08:00AM  VIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of Korea Marketwired
Sep-04-17 08:29AM  VIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound? Zacks
Aug-30-17 04:05PM  VIVUS Announces Settlement with Dr. Reddy's Laboratories on Qsymia(R) Patent Litigation Marketwired
Aug-22-17 08:00AM  VIVUS to Present at 2017 Wells Fargo Healthcare Conference on September 7, 2017 Marketwired
Aug-10-17 08:00AM  Vivus Pipeline Review, Analysis and Potential Catalysts ACCESSWIRE
Aug-07-17 09:40AM  VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y Zacks
Aug-03-17 04:15PM  VIVUS Reports Second Quarter 2017 Financial Results Marketwired
Jul-06-17 10:06AM  VIVUS Settles with Teva on Weight Management Drug Generic Zacks
Jul-05-17 04:15PM  VIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation Marketwired
Jul-03-17 10:11AM  BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase Zacks
09:44AM  Roche (RHHBY) Launches Cobas Test for Bacterial Infections Zacks
Jun-30-17 10:46AM  Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label Zacks
10:07AM  Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU Zacks
10:02AM  Acorda Files NDA for Parkinson's Disease Candidate Inbrija Zacks
Jun-29-17 10:49AM  Valeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA Zacks
10:40AM  KemPharm (KMPH) Strengthens its ADHD Prodrug Pipeline Zacks
Jun-28-17 01:20PM  Neothetics' Fat Reduction Candidate Fails in Phase II Study Zacks
08:24AM  Teva/Xenon Nerve Pain Candidate Fails in Phase II Study Zacks
Jun-27-17 10:48AM  Seattle Genetics (SGEN) Reports Positive Data for Adcetris Zacks
10:01AM  Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti Zacks
Jun-22-17 10:54AM  Shire (SHPG) Receives MAA Validation for Veyvondi by EMA Zacks
10:06AM  Glaxo's (GSK) Shingles Candidate Phase III Data Positive Zacks
10:03AM  Indivor's Opioid Use Disorder Drug Meets Primary Endpoint Zacks
09:47AM  Novartis Announces Positive Results for Cardiovascular Drug Zacks
08:37AM  BioMarin (BMRN) in Focus: Stock Moves 7% Higher Zacks
08:15AM  Myriad Genetics (MYGN) Catches Eye: Stock Moves Up 5.7% Zacks
Jun-21-17 10:52AM  Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US Zacks
08:15AM  Agenus (AGEN) Looks Good: Stock Moves Up 9.6% in Session Zacks
Jun-20-17 02:55PM  Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada Zacks
11:21AM  Rigel Pharmaceuticals' NDA for Tavalisse Accepted by FDA Zacks
10:33AM  Merrimack Completes Enrollment in Phase II Study for MM-141 Zacks
10:31AM  Seattle Genetics Halts Phase III Study on Leukemia Drug Zacks
08:15AM  Fibrocell Science (FCSC) Looks Good: Stock Moves Up 13.9% Zacks
Jun-19-17 10:52AM  Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205 Zacks
08:34AM  AveXis (AVXS) Surges: Stock Moves 5% Higher Zacks
Jun-16-17 04:22PM  Mallinckrodt Initiates Amyotrophic Lateral Sclerosis Study Zacks
10:53AM  Omeros (OMER) Hits New 52-Week High on Positive FDA Decision Zacks
08:35AM  Epizyme (EPZM) Jumps: Stock Rises 17.4% Zacks
08:25AM  Selecta Biosciences (SELB) In Focus: Stock Moves 6.5% Higher Zacks
08:15AM  NantKwest (NK) Looks Good: Stock Moves Up 8.5% in Session Zacks
Jun-15-17 05:45PM  Celgene (CELG) Reports Data on Lupus Drug in Phase II Trial Zacks
Jun-14-17 03:25PM  Acceleron (XLRN) Kidney Cancer Candidate Fails in Phase II Zacks
10:27AM  Omeros (OMER) Lead Candidate Gets Breakthrough Designation Zacks
09:09AM  Novo Nordisk (NVO) Presents Data for Type II Diabetes Drug Zacks
Jun-13-17 05:32PM  Exelixis Initiates Cabozantinib-Tecentriq Combination Trial Zacks
05:16PM  Gilead (GILD) Submits NDA for HIV Combination Therapy Regimen Zacks
10:16AM  Seres Therapeutics' Stock Up as SER-109 Moves to Phase III Zacks
10:14AM  GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up Zacks
10:03AM  Intercept (ICPT) Releases Data from Phase II Flint Trial Zacks
09:37AM  Amgen's Multiple Myeloma Drug Receives NICE Recommendation Zacks
VIVUS, Inc., a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also involved in developing Qsymia, which has been completed Phase II studies for the treatment of various diseases, including obstructive sleep apnea and diabetes, nonalcoholic steatohepatitis and fatty liver disease, hyperlipidemia, and hypertension, as well as Tacrolimus that has been completed Phase IIa studies for the treatment of pulmonary arterial hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin Chemie AG to commercialize and promote STENDRA. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROSENMAN HERMDirectorJun 29Option Exercise0.7025,00017,500311,671Jul 03 04:10 PM
ROSENMAN HERMDirectorJun 01Buy0.7750,00038,50050,000Jun 05 09:31 PM
ROSENMAN HERMDirectorMay 29Buy0.7950,00039,500286,671May 31 04:33 PM
ROSENMAN HERMDirectorMay 21Option Exercise0.7075,00052,500136,671May 23 05:05 PM
ROSENMAN HERMDirectorMay 21Buy0.81100,00081,000236,671May 23 05:05 PM
Amos John P.Chief Executive OfficerMay 18Buy0.77270,000208,0891,710,000May 22 05:08 PM
Amos John P.Chief Executive OfficerMay 18Sale0.771,5001,1561,708,500May 22 05:08 PM
Amos John P.Chief Executive OfficerMay 17Buy0.69360,000249,2281,440,000May 21 07:16 PM
Amos John P.Chief Executive OfficerMay 16Buy0.58270,000156,5461,080,000May 17 05:00 PM
Amos John P.Chief Executive OfficerMay 15Buy0.54270,000146,529810,000May 17 05:00 PM
Amos John P.Chief Executive OfficerMay 14Buy0.51270,000138,672540,000May 15 07:39 PM
Amos John P.Chief Executive OfficerMay 11Buy0.52270,000139,914270,000May 15 07:39 PM
Varghese Santosh TChief Medical OfficerApr 03Sale0.3439013271,415Apr 04 04:22 PM
Varghese Santosh TChief Medical OfficerJan 31Sale0.4349121171,805Feb 01 04:19 PM
Varghese Santosh TChief Medical OfficerJan 01Sale0.5144422672,296Jan 03 07:09 PM
Varghese Santosh TChief Medical OfficerOct 03Sale0.9743442172,740Oct 04 04:42 PM